Back to Search
Start Over
HLA ligandome tumor antigen discovery for personalized vaccine approach.
- Source :
- Expert Review of Vaccines; Oct2013, Vol. 12 Issue 10, p1211-1217, 7p
- Publication Year :
- 2013
-
Abstract
- Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usually not used in the adult organism. The search for cancer-associated antigens shared by many patients with a particular cancer has yielded a number of hits used in clinical vaccination trials with indication of survival benefit. Targeting cancer-specific antigens, which are exclusively expressed on cancer cells and not on normal cells, holds the promise for much better results and perhaps even a cure. Such antigens, however, may specifically appear in very few patients or may be mutated appearing just in one patient. Therefore, to target these in a molecularly defined way, the approach has to be individualized. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14760584
- Volume :
- 12
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Expert Review of Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 90815196
- Full Text :
- https://doi.org/10.1586/14760584.2013.836911